eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

2/2022
vol. 14
 
Share:
Share:
more
 
 
abstract:
Case report

High-dose-rate interstitial brachytherapy as a suitable option for metastatic extraskeletal myxoid chondrosarcoma – a case report

Yoshiaki Takagawa
1, 2
,
Naoya Murakami
2
,
Hiroshi Igaki
2
,
Hiroyuki Okamoto
3
,
Jun Itami
2, 4

1.
Department of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, Fukushima, Japan
2.
Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
3.
Department of Medical Physics, National Cancer Center Hospital, Tokyo, Japan
4.
Department of Radiation Therapy Center, Shin-Matsudo Central General Hospital, Chiba, Japan
J Contemp Brachytherapy 2022; 14, 2: 198–204
Online publish date: 2022/03/31
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
We report on a patient with metastatic extraskeletal myxoid chondrosarcoma (EMC), who was treated with palliative high-dose-rate (HDR) interstitial brachytherapy (ISBT). The patient was an 87-year-old woman who underwent an amputation for a bulky tumor in her right ankle joint. EMC was histopathologically confirmed. She presented with a large right inguinal lymph node metastasis of EMC 16 months after surgery. Palliative HDR-ISBT (30 Gy/2 fractions in 1 day) for the right inguinal lymph node metastasis was administered to shorten treatment period. Additional HDR-ISBT (30 Gy/2 fractions in 1 day) was administered for the management of subsequent subcutaneous metastasis to the right breast and right popliteal fossa. HDR-ISBT provided significant long-term control of the recurrent tumor in all three sites, without severe acute and late toxicity. Thus, HDR-ISBT regimen of 30 Gy/2 fractions in 1 day can be a suitable option for both palliation and long-term local control for patients with metastatic EMC.
keywords:

extraskeletal myxoid chondrosarcoma, palliation, high-dose-rate, interstitial brachytherapy

 
Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.